Clinical trial · no report yet · Phase 3
SERENA-4
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- NCT04711252 ↗
- Active not recruiting
- AstraZeneca
- 90 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 42 | |
| Podcasts | 32 | |
| X threads | 15 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- AZD9833; Anastrozole; Anastrozole placebo; AZD9833 placebo; Palbociclib; Luteinizing hormone-releasing hormone (LHRH) agonist
- Arms
- AZD9833 + palbociclib · Experimental
- Anastrozole + palbociclib · Active comparator
- Enrollment
- 1,371
- Primary outcomes
- Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1
- Sponsor
- AstraZeneca
- Start
- Jan 28, 2021
- Primary completion
- Jun 26, 2026
- Results posted
- No
- Registry record
- NCT04711252 · updated Sep 28, 2026